Fast Track AWAK
Based on successful human trials in Japan, a WAK wearable PD system using sorbent technology received FDA fast track status this year. With thrice-daily use, the device removed toxins and had no serious adverse events. And, since dialysate is regenerated, dramatically less fluid volume can be used.
Read the full article » | Posted 10-14-2019
Related Articles
- Proof of Concept for Silicon Nanopore Membrane Implantable HD Posted 10-05-2026
- AWAK PD To Go Posted 10-05-2026
- The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
- Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026

